Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.62 |
| ▸ | TACR1 | P25103 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9712338 | 1.00 | AGTR2 (0.62) | AGTR2TACR1ALDH1A1 | |
| Acetic Acid SCHEMBL7387159 | 0.96 | AGTR2 (0.58) | AGTR2TACR1ALDH1A1 | |
| Acetic Acid SCHEMBL7387154 | 0.96 | AGTR2 (0.58) | AGTR2TACR1ALDH1A1 | |
| SCHEMBL7422576 | 0.90 | AGTR2 (0.52) | AGTR2TACR1ALDH1A1 | |
| SCHEMBL7422588 | 0.90 | AGTR2 (0.52) | AGTR2TACR1ALDH1A1 | |
| SCHEMBL7385924 | 0.89 | AGTR2 (0.51) | AGTR2TACR1ALDH1A1 | |
| SCHEMBL7385930 | 0.89 | AGTR2 (0.51) | AGTR2TACR1ALDH1A1 | |
| SCHEMBL30743875 | 0.89 | AGTR2 (0.52) | AGTR2TACR1ALDH1A1 | |
| Acetic Acid SCHEMBL7384587 | 0.88 | AGTR2 (0.50) | AGTR2TACR1 | |
| Bromide SCHEMBL7378735 | 0.88 | TACR1 (0.53) | AGTR2TACR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395231-A1 | RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| EP-3760620-A1 | RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2019161781-A1 | RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF | 北京泰德制药股份有限公司 | 2019-08-29 | — | — | WO | disclosed |
| WO-1992020661-A1 | N, N-DIACYLPIPERAZINES | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395231-A1 | RECEPTOR INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | TACR1, TACR2, GPBAR1 | AGTR2 13/4885TACR1 1/4885ALDH1A1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.